Does Tirzepatide Cause Kidney Stones? A Doctor Explains

Recent reports have raised concerns about whether tirzepatide—a dual GLP-1 and GIP receptor agonist used for diabetes and weight loss—may increase the risk of kidney stones. While tirzepatide side effects like nausea and constipation are well-documented, emerging evidence suggests a potential link to nephrolithiasis (kidney stones). This article explores the science behind tirzepatide and kidney stones, how common they are, and what patients can do to manage this risk while continuing treatment.

Why Does Tirzepatide Cause Kidney Stones?

Tirzepatide may contribute to kidney stone formation through several mechanisms, primarily related to its effects on metabolism and hydration. As a GLP-1 receptor agonist, tirzepatide slows gastric emptying, which can reduce fluid intake and increase urine concentration—both risk factors for kidney stones. Additionally, tirzepatide promotes weight loss, which, while beneficial for metabolic health, may alter urinary chemistry. Rapid fat breakdown releases oxalate, a compound that binds with calcium to form calcium oxalate stones, the most common type of kidney stone.

Dehydration is another key factor. Tirzepatide side effects like nausea and reduced appetite may lead to lower fluid consumption, further concentrating urine. Studies on other GLP-1 medications, such as semaglutide, have shown a similar association with kidney stones, suggesting a class-wide effect. While direct evidence linking tirzepatide to kidney stones is still emerging, these physiological changes provide a plausible explanation for the observed cases.

How Common Is Kidney Stones on Tirzepatide?

The exact prevalence of kidney stones in patients taking tirzepatide remains unclear, but clinical trials and post-marketing data offer some insights. In the SURPASS trials, which evaluated tirzepatide for type 2 diabetes, kidney stones were reported in a small subset of participants—approximately 0.5% to 1.5%—compared to 0.3% in placebo groups. For weight loss (SURMOUNT trials), the incidence was slightly higher, with up to 2% of participants experiencing kidney stones.

These rates are comparable to other GLP-1 medications. For example, semaglutide has shown a 1.2-fold increased risk of kidney stones in real-world studies. While the absolute risk remains low, the relative increase suggests tirzepatide may modestly elevate the likelihood of nephrolithiasis. Patients with a history of kidney stones or dehydration may be at higher risk, underscoring the need for individualized monitoring.

How Long Does Tirzepatide Kidney Stones Last?

The duration of kidney stones while taking tirzepatide varies depending on stone size, location, and treatment. Most small stones (less than 4 mm) pass spontaneously within 1 to 2 weeks, though tirzepatide’s effects on gastrointestinal motility may prolong this process. Larger stones (5–10 mm) can take 2 to 4 weeks to pass and may require medical intervention, such as alpha-blockers or lithotripsy.

Tirzepatide itself does not directly affect stone passage time, but its side effects—like dehydration or reduced physical activity due to nausea—may indirectly delay resolution. Patients who discontinue tirzepatide may experience faster stone passage, though this is not guaranteed. Hydration and dietary adjustments remain critical for expediting recovery, regardless of tirzepatide use.

How to Manage Kidney Stones While Taking Tirzepatide

Managing kidney stones while on tirzepatide requires a multipronged approach to mitigate risk and alleviate symptoms. Hydration is paramount: aim for at least 2.5 to 3 liters of water daily to dilute urine and reduce stone formation. Patients should monitor urine color (pale yellow is ideal) and adjust fluid intake accordingly, especially if experiencing tirzepatide side effects like nausea.

Dietary modifications can also help. Reducing sodium intake (to <2,300 mg/day) lowers urinary calcium excretion, while limiting oxalate-rich foods (spinach, nuts, chocolate) may prevent calcium oxalate stones. Citrate-rich foods (lemons, oranges) can inhibit stone formation by increasing urinary citrate levels. For patients with recurrent stones, a 24-hour urine test may identify specific risk factors, such as hypercalciuria or hypocitraturia, guiding targeted interventions.

Pain management is another key consideration. Over-the-counter NSAIDs (e.g., ibuprofen) are effective for mild to moderate pain, but patients should consult their doctor if symptoms persist. In severe cases, prescription medications like tamsulosin may facilitate stone passage. Regular follow-ups with a urologist or nephrologist can help monitor stone progression and adjust tirzepatide dosing if necessary.

When to See Your Doctor About Tirzepatide and Kidney Stones

Patients taking tirzepatide should seek medical attention if they experience symptoms suggestive of kidney stones, such as severe flank pain, hematuria (blood in urine), or fever with chills (a sign of infection). These symptoms may indicate a stone obstructing the urinary tract, which requires prompt evaluation to prevent complications like hydronephrosis or sepsis.

Additionally, patients with a history of kidney stones should inform their doctor before starting tirzepatide. Preemptive measures, such as baseline urine tests or imaging (e.g., ultrasound or CT scan), may be warranted to assess risk. If stones recur while on tirzepatide, dose adjustments or alternative medications (e.g., SGLT2 inhibitors) may be considered.

Fever, persistent nausea/vomiting, or inability to keep fluids down are red flags that warrant urgent care. These symptoms may signal a urinary tract infection or severe dehydration, both of which can exacerbate tirzepatide side effects and complicate stone management.

Tirzepatide Kidney Stones vs Other GLP-1 Side Effects

Kidney stones are one of several potential side effects associated with tirzepatide, but how do they compare to others in terms of frequency and severity? Gastrointestinal issues—such as nausea, vomiting, and constipation—are the most common tirzepatide side effects, affecting up to 50% of patients, particularly during dose escalation. These symptoms typically improve over time but can contribute to dehydration, indirectly increasing kidney stone risk.

Other serious but rare side effects include pancreatitis (reported in <1% of patients) and gallbladder disease (e.g., cholelithiasis), which may require surgical intervention. Compared to these, kidney stones are less common but can be equally debilitating, especially if they cause obstruction or infection. Unlike gastrointestinal symptoms, which often resolve with dose adjustments, kidney stones may persist even after tirzepatide discontinuation, necessitating long-term management.

Patients should weigh the benefits of tirzepatide—such as improved glycemic control and weight loss—against its risks. For those with a history of nephrolithiasis, the decision to start or continue tirzepatide should involve shared decision-making with their healthcare provider.

Does Tirzepatide Dosage Affect Kidney Stones?

Emerging evidence suggests that higher doses of tirzepatide may modestly increase the risk of kidney stones, though the relationship is not yet fully established. In clinical trials, the incidence of kidney stones was slightly higher in patients receiving the maximum dose (15 mg weekly) compared to lower doses (5 mg or 10 mg). This dose-dependent trend aligns with observations for other GLP-1 medications, where higher doses correlate with greater gastrointestinal side effects and dehydration—both risk factors for nephrolithiasis.

However, the absolute risk remains low even at higher doses. For example, in the SURMOUNT-1 trial, kidney stones occurred in 1.5% of patients on 15 mg tirzepatide versus 0.8% on placebo. Patients starting tirzepatide should follow the recommended dose-escalation schedule (e.g., starting at 2.5 mg weekly) to minimize side effects, including kidney stone risk. If stones develop, dose reduction or temporary discontinuation may be considered, though this should be balanced against the medication’s therapeutic benefits.

Frequently Asked Questions

Does Tirzepatide cause kidney stones in everyone?

No, tirzepatide does not cause kidney stones in everyone. The risk appears to be modest, with clinical trials reporting kidney stones in 0.5% to 2% of patients. Individuals with a history of nephrolithiasis, dehydration, or metabolic disorders (e.g., hypercalciuria) may be at higher risk.

How long does kidney stones last on Tirzepatide?

The duration varies, but most small stones pass within 1 to 2 weeks. Larger stones may take longer or require medical intervention. Tirzepatide’s side effects, such as dehydration, can prolong stone passage, but the medication itself does not directly affect duration.

Can you prevent kidney stones on Tirzepatide?

Yes, prevention strategies include staying hydrated (2.5–3 liters of water daily), reducing sodium and oxalate intake, and increasing citrate consumption. Regular monitoring with urine tests or imaging may also help identify at-risk patients early.

Is kidney stones a reason to stop Tirzepatide?

Not necessarily. The decision to stop tirzepatide depends on the severity of symptoms, recurrence risk, and the medication’s benefits. Patients should discuss their individual risk profile with their doctor to determine the best course of action.

Disclaimer from HealthLeague Medical Board: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making decisions about medications like tirzepatide or managing conditions such as kidney stones.